All over the world, many countries are facing aging populations while at the same time the total world population has continued to grow. The potential to live longer than ever before has also come with an increase in chronic diseases and a greater demand for new treatments. Pharmaceutical companies are embracing digital technology to aid their research and discovery, while at the same time reaffirming a commitment to using more sustainable methods.
Today’s advanced modeling simulation capabilities offer the opportunity for drugs, medical devices, and other therapeutics to be tested, validated, and moved to development sooner. Likewise, effective use of process data can be a major competitive advantage for a company, enabling better supply chain efficiency, regulatory compliance, and speed to market. Sometimes these digital advancements can seem futuristic even to those working in the industry. Daniel Matlis, president of Life Sciences industry analyst firm Axendia relates,
“When I talk to executives and we discuss modeling and simulation, using the example of the Living Heart Project, the reaction that I get most often is, ‘This cannot be real. This cannot be happening today’… They need to recognize that these technologies are not simply buzzwords. We need to shift from the paradigm that all these technologies are science fiction and realize that they’re science fact.”
Helping to drive much of this innovation is the Dassault Systèmes 3DEXPERIENCE platform, offering solutions that enable immediate access to process and quality data from a variety of disparate databases throughout the cloud. The cloud-based platform makes big operational data much easier to manage, less expensive to implement, and reduces development time.
Digital systems that support and streamline the entire end-to-end pharmaceutical manufacturing process ultimately lead to improved safety, lower costs, increased collaboration, and most importantly better health outcomes for patients.
Interested in learning more? Read the latest article on sustainable pharmaceutical manufacturing by Rebecca Lambert in our Compass magazine.
